Examines how insurance benefit design, including high deductibles and co-insurance, impact prescription drug access, along with the importance of copay assistance and how states are ensuring that it count towards beneficiary cost-sharing obligations.
Details policies and programs needed to ensure and promote PrEP access to #endHIV: reviewing insurance plans to see if they follow the ACA requirement to cover PrEP w/o patient cost-sharing, the need for greater funding of @CDC_HIVAIDS & community health centers, & potential USPSTF evaluation of long-acting PrEP products
Provides details on how insurers’ treatment of manufacturer copay assistance affects patients’ out-of-pocket spending and how high costs drive up prescription abandonment rates, especially while patients deal with the economic effects of COVID.
Provides an update on the growing practice by insurance company and PBMs that do not count copay assistance for prescription drugs towards a beneficiary’s deductible and out-of-pocket spending limits. Discusses the impact on patients and what it is being done at the state and federal levels to stop this practice.